Indegene Ltd

Indegene Ltd

₹ 548 -1.85%
30 Apr - close price
About

Incorporated in 1998, Indegene Ltd provides
solutions consisting of analytics, technology
and commercial, medical, regulatory and
safety services to life science and health
care organizations[1]

Key Points

Business Overview:[1]
IL is a digital-first healthcare and technology company. It helps bio pharmaceutical, emerging biotech and medical device companies to develop products and get them to market. Company brings together healthcare domain expertise, technology and an agile operating model to provide diverse solutions for patients and physicians.

  • Market Cap 13,148 Cr.
  • Current Price 548
  • High / Low 737 / 469
  • Stock P/E 32.3
  • Book Value 109
  • Dividend Yield 0.00 %
  • ROCE 24.2 %
  • ROE 20.1 %
  • Face Value 2.00

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has delivered good profit growth of 67.2% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 24.1%

Cons

  • Working capital days have increased from 97.7 days to 208 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
632 608 636 673 673 676 687 720 756
535 511 515 524 534 548 561 589 608
Operating Profit 97 97 121 149 139 129 126 132 148
OPM % 15% 16% 19% 22% 21% 19% 18% 18% 20%
13 28 12 13 26 22 21 38 26
Interest 12 13 12 12 12 12 4 3 3
Depreciation 20 20 20 18 18 20 19 20 21
Profit before tax 79 92 101 132 134 120 124 146 149
Tax % 38% 26% 25% 25% 29% 27% 26% 25% 21%
49 68 75 99 95 88 92 110 118
EPS in Rs 2.20 3.08 3.38 4.45 4.26 3.67 3.83 4.58 4.90
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
553 643 966 1,665 2,306 2,590 2,839
511 499 736 1,378 1,910 2,084 2,305
Operating Profit 42 144 230 287 396 505 534
OPM % 8% 22% 24% 17% 17% 20% 19%
7 -102 -3 -21 58 79 107
Interest 6 9 7 6 31 49 22
Depreciation 17 19 26 33 60 76 80
Profit before tax 26 14 195 226 363 459 539
Tax % 45% 191% 23% 28% 27% 27% 25%
14 -12 149 163 266 337 407
EPS in Rs 89.98 -40.20 951.96 937.73 11.99 15.14 16.95
Dividend Payout % 0% 0% 0% 0% 0% 0% 12%
Compounded Sales Growth
10 Years: %
5 Years: 35%
3 Years: 19%
TTM: 10%
Compounded Profit Growth
10 Years: %
5 Years: 67%
3 Years: 29%
TTM: 21%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: 28%
3 Years: 24%
Last Year: 20%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 0.31 0.31 0.31 0.35 44 44 48
Reserves 73 -105 324 764 1,020 1,385 2,568
147 483 51 66 502 490 102
108 222 220 524 638 627 609
Total Liabilities 329 600 596 1,353 2,204 2,546 3,326
104 119 86 138 664 646 678
CWIP 0 0 0 0 0 0 4
Investments 0 13 0 120 614 796 1,290
225 468 510 1,096 926 1,103 1,355
Total Assets 329 600 596 1,353 2,204 2,546 3,326

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
65 22 172 297 130 508 442
-18 -16 -81 -158 -896 -326 -683
-21 136 -132 233 333 -66 288
Net Cash Flow 25 143 -40 373 -433 115 47

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 60 127 108 97 102 91 81
Inventory Days
Days Payable
Cash Conversion Cycle 60 127 108 97 102 91 81
Working Capital Days 23 64 53 16 45 40 208
ROCE % 37% 55% 46% 33% 29% 24%

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025
3.79% 4.82% 5.03% 5.24%
3.84% 3.17% 3.99% 4.96%
92.38% 92.01% 91.01% 89.80%
No. of Shareholders 2,03,5991,51,4401,53,7891,44,708

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents